The results show that with the disease progression, APOE ε4 carriers had alterations in metabolites associated with increased Aβ retention, reducing atherosclerosis, and the impaired TCA cycle and oxidative phosphorylation. The gene discussed is APOE; the disease is atherosclerosis.